Abstract
Background
Little is known regarding the prognostication of the Pan-Immune-Inflammation Value (PIV) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Objectives
This study aimed to investigate the prognostic role of PIV in patients with R/M HNSCC receiving immune checkpoint inhibitors (ICI).
Patients and Methods
Patients who were diagnosed to have R/M HNSCC and treated with ICI were reviewed retrospectively. The cutoff value of PIV was set at the median. Patients were stratified into high PIV and low PIV. Kaplan–Meier curves were estimated for progression-free survival (PFS) and overall survival (OS).
Results
A total of 192 patients were included in our study for oncologic outcomes evaluation. For the total population, the median PFS was 5.5 months and OS was 18.2 months. After stratification by PIV, median PFS was 11.7 months in the low PIV and 2.8 months in the high PIV groups (p < 0.001). The median OS was 21.8 months in the low PIV and 11.5 months in the high PIV groups (p < 0.001). Multivariate analysis demonstrated that PIV and PD-L1 were independent predictors associated with survival. A prognostic model using both PIV and PD-L1 was constructed. The median PFS was 12.2, 6.4, and 3.0 months for patients with risk scores of 0, 1, and 2, respectively (p < 0.001). The median OS was 23.7, 18.1, and 11.4 months for patients with risk scores of 0, 1, and 2, respectively (p < 0.001).
Conclusions
PIV is a prognostic biomarker in patients with R/M HNSCC treated with ICI. A prognostic model using PIV and PD-L1 could provide outcome prediction and risk stratification.
Similar content being viewed by others
References
Chow LQM. Head and neck cancer. N Engl J Med. 2020;382:60–72. https://doi.org/10.1056/NEJMra1715715.
Aupérin A. Epidemiology of head and neck cancers: an update. Curr Opin Oncol. 2020;32:178–86. https://doi.org/10.1097/CCO.0000000000000629.
Szturz P, Vermorken JB. Management of recurrent and metastatic oral cavity cancer: raising the bar a step higher. Oral Oncol. 2020;101: 104492. https://doi.org/10.1016/j.oraloncology.2019.104492.
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–28. https://doi.org/10.1016/S0140-6736(19)32591-7.
Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and Neck. N Engl J Med. 2016;375:1856–67. https://doi.org/10.1056/NEJMoa1602252.
Gavrielatou N, Doumas S, Economopoulou P, et al. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 2020;84: 101977. https://doi.org/10.1016/j.ctrv.2020.101977.
Ma SJ, Yu H, Khan M, et al. Evaluation of optimal threshold of neutrophil-lymphocyte ratio and its association with survival outcomes among patients with head and neck cancer. JAMA Netw Open. 2022;5: e227567. https://doi.org/10.1001/jamanetworkopen.2022.7567.
Kumarasamy C, Tiwary V, Sunil K, et al. Prognostic utility of platelet-lymphocyte ratio, neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in head and neck cancers: a detailed PRISMA compliant systematic review and meta-analysis. Cancers (Basel). 2021;13:4166. https://doi.org/10.3390/cancers13164166.
Ma X, Ding Y, Qian J, et al. Nomogram based on monocyte-to-lymphocyte ratio to predict survival of unresectable esophageal squamous cell carcinoma who receive first-line PD-1/PD-L1 inhibitors combined with chemotherapy. Curr Oncol. 2022;29:8937–54. https://doi.org/10.3390/curroncol29110702.
Terazawa K, Ohashi T, Shibata H, et al. Immune-modified Glasgow prognostic score: a new prognostic marker for head and neck cancer. Head Neck. 2022;44:2555–63. https://doi.org/10.1002/hed.27170.
Wang YT, Kuo LT, Weng HH, et al. Systemic immune-inflammation index as a predictor for head and neck cancer prognosis: a meta-analysis. Front Oncol. 2022;12: 899518. https://doi.org/10.3389/fonc.2022.899518.
Yang XC, Liu H, Liu DC, et al. Prognostic value of pan-immune-inflammation value in colorectal cancer patients: a systematic review and meta-analysis. Front Oncol. 2022;12:1036890. https://doi.org/10.3389/fonc.2022.1036890.
Guven DC, Erul E, Yilmaz F, et al. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2023;280(5):2471–8. https://doi.org/10.1007/s00405-022-07804-x.
Yeh CC, Kao HK, Huang Y, et al. Discovering the clinical and prognostic role of pan-immune-inflammation values on oral cavity squamous cell carcinoma. Cancers (Basel). 2023;15:322. https://doi.org/10.3390/cancers15010322.
Sahin AA, Gilligan TD, Caudell JJ. Challenges With the 8th Edition of the AJCC cancer staging manual for breast, testicular, and head and neck cancers. J Natl Compr Canc Netw. 2019;1:560–4.
Fucà G, Guarini V, Antoniotti C, et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer. 2020;123:403–9.
Corti F, Lonardi S, Intini R, et al. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer. 2021;150:155–67. https://doi.org/10.1016/j.ejca.2021.03.043.
Şahin AB, Cubukcu E, Ocak B, et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Sci Rep. 2021;11:14662. https://doi.org/10.1038/s41598-021-94184-7.
Chen X, Hong X, Chen G, et al. The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor. Transl Oncol. 2021;17: 101338. https://doi.org/10.1016/j.tranon.2021.101338.
Fucà G, Beninato T, Bini M, et al. The Pan-Immune-Inflammation Value in Patients with metastatic melanoma receiving first-line therapy. Target Oncol. 2021;16:529–36. https://doi.org/10.1007/s11523-021-00819-0.
Yazgan SC, Yekedüz E, Utkan G, et al. Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors. Prostate. 2022;82:1456–61. https://doi.org/10.1002/pros.24419.
Topkan E, Selek U, Kucuk A, et al. Low pre-chemoradiotherapy Pan-Immune-Inflammation Value (PIV) measures predict better survival outcomes in locally advanced pancreatic adenocarcinomas. J Inflamm Res. 2022;18:5413–23. https://doi.org/10.2147/JIR.S385328.
Wang SB, Chen JY, Xu C, et al. Evaluation of systemic inflammatory and nutritional indexes in locally advanced gastric cancer treated with adjuvant chemoradiotherapy after D2 dissection. Front Oncol. 2022;12:1040495. https://doi.org/10.3389/fonc.2022.1040495.
Guven DC, Sahin TK, Erul E, et al. The association between the Pan-Immune-Inflammation Value and cancer prognosis: a systematic review and meta-analysis. Cancers. 2022;14:2675. https://doi.org/10.3390/cancers14112675.
Kayar R, Bastug Y, Tokuc E, et al. Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer. Int Urol Nephrol. 2023. https://doi.org/10.1007/s11255-023-03812-w.
Provenzano L, Lobefaro R, Ligorio F, et al. The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis. Ther Adv Med Oncol. 2023;15:17588359231165978. https://doi.org/10.1177/17588359231165978.
Kucuk A, Topkan E, Ozkan EE, et al. A high pan-immune-inflammation value before chemoradiotherapy indicates poor outcomes in patients with small-cell lung cancer. Int J Immunopathol Pharmacol. 2023;37:3946320231187759. https://doi.org/10.1177/03946320231187759.
Zhao H, Chen X, Zhang W, et al. Pan-immune-inflammation value is associated with the clinical stage of colorectal cancer. Front Surg. 2022;9: 996844. https://doi.org/10.3389/fsurg.2022.996844.
Barker T, Fulde G, Moulton B, et al. An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer. Sci Rep. 2020;10:7355.
Ligorio F, Fucà G, Zattarin E, et al. The Pan-Immune-Inflammation-Value predicts the survival of patients with human epidermal growth factor receptor 2 (HER2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab. Cancers. 2021;13:1964.
Roxburgh CS, McMillan DC. Cancer and systemic inflammation: Treat the tumour and treat the host. Br J Cancer. 2014;110:1409–12. https://doi.org/10.1038/bjc.2014.90.
Cook J, Hagemann T. Tumour-associated macrophages and cancer. Curr Opin Pharmacol. 2013;4:595–901. https://doi.org/10.1016/j.coph.2013.05.017.
Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123–34. https://doi.org/10.1038/nrc3004.
Acknowledgements
This work was supported by grants from E-Da Cancer Hospital (Grant no. EDCHP109012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The authors received no financial support for the research, authorship, and/or publication of this article.
Conflict of interest/Competing interests
Ming-Yu Lien, Tzer-Zen Hwang, Chih-Chun Wang, Ching-Yun Hsieh, Chuan-Chien Yang, Chien-Chung Wang, Ching-Feng Lien, Yu-Chen Shih, Shyh-An Yeh, and Meng-Che Hsieh declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.
Author contributions
MYL, TZH, CCW (Chih-Chun Wang) and MCH developed the study design. CYH, CCY, and CCW (Chien-Chung Wang) collected data. All authors critically reviewed and approved final draft and are accountable for accuracy and integrity.
Data availability
The datasets that support the findings of this study are available from the corresponding (M.C.H.) upon reasonable request.
Ethical approval
This study was approved by the E-Da Hospital Institutional Review Board (EMRP70110N) and was conducted in accordance with the Declaration of Helsinki.
Consent to participate
Written informed consent was waived because this is a retrospective study.
Consent to publish
All authors provided consent for publication.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Lien, MY., Hwang, TZ., Wang, CC. et al. A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis. Targ Oncol 19, 71–79 (2024). https://doi.org/10.1007/s11523-023-01018-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-023-01018-9